Showing 1 - 10 of 103
Persistent link: https://www.econbiz.de/10011393507
Compared with developed economies, health expenditure in China is not particularly high on a per capita basis or as a share of Gross Domestic Product (GDP). Similarly, pharmaceutical expenditure in comparative perspective is not particularly high on a per capita basis or as a percentage of GDP....
Persistent link: https://www.econbiz.de/10012247334
This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it …
Persistent link: https://www.econbiz.de/10012247481
The COVID-19 pandemic has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Despite rapid development of a range of COVID-19 vaccines using innovative technologies, access to these vaccines has been a challenge, with manufacturing mostly...
Persistent link: https://www.econbiz.de/10014578934
COVID-19 has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Despite rapid development of a range of COVID-19 vaccines using innovative technologies, access to these vaccines has been a challenge, with manufacturing mostly concentrated in the...
Persistent link: https://www.econbiz.de/10014579804
Persistent link: https://www.econbiz.de/10010523369
Persistent link: https://www.econbiz.de/10010523456
Persistent link: https://www.econbiz.de/10010523457
Health experts and policymakers want people to have access to affordable and high-quality medical care. But in some developing countries, making quality healthcare available may first necessitate ensuring that essential medicines are available, such as anti-malaria pills and antibiotics. The...
Persistent link: https://www.econbiz.de/10012560953